SECsense Logo

T2 Biosystems Inc. 8-K Filing Report: Key Insights for December 30, 2024

$TTOO
Form 8-K
Filed on: 2025-01-03
Source
T2 Biosystems Inc. 8-K Filing Report: Key Insights for December 30, 2024

Based on the provided section of the financial report, here are the key information and insights extracted:

  1. Company Identifier:
  • Name: T2 Biosystems, Inc.
  • CIK: 0001492674
  • State of Incorporation: Delaware (DE)
  • SEC File Number: 001-36571
  • EIN: 20-4827488
  1. Address:
  • Location: 101 Hartwell Avenue, Lexington, MA 02421
  • Phone Number: (781) 761-4646
  1. Stock Information:
  • Type of Stock: Common stock
  • Par Value: $0.001 per share
  • Ticker Symbol: TTOO
  • Exchange: NASDAQ
  1. Filing Details:
  • Form Type: 8-K
  • Filing Date: December 30, 2024
  1. Reporting Period:
  • The reporting period is a single day, specifically December 30, 2024.
  1. XML/XBRL Information:
  • The document is formatted in XBRL (eXtensible Business Reporting Language), which is commonly used for SEC filings to facilitate automated analysis and reporting.

Insights:

  • The filing date of December 30, 2024, indicates that this report contains information that is relevant to investors and stakeholders for that specific date.
  • The company operates in a biotech space, indicated by its name, and is listed on NASDAQ, which may suggest it is under regulatory scrutiny and subject to the requirements of public company reporting.
  • The common stock has a very low par value, which may indicate a strategy focused on raising capital through the issuance of shares.
  • The report's submission on an 8-K form suggests that it may contain significant events or corporate changes that require immediate disclosure to the public and investors.

This section provides a snapshot of T2 Biosystems, Inc.'s corporate identity, stock details, and the nature of its SEC filing, which is crucial for potential investors and analysts tracking the company's performance and compliance.